Previous 10 | Next 10 |
Toronto, Ontario--(Newsfile Corp. - February 15, 2023) - Moneta Gold Inc. (TSX: ME) (OTCQX: MEAUF) (FSE: MOPA) ("Moneta") is pleased to announce assay results from thirty (30) resource infill and step-out drill holes on the 903 gold deposit at the Tower Gold project (the "Project"), located in ...
Genetics company 23andMe (NASDAQ: ME) hasn't exactly been a strong performer, with shares down by about 73% since it went public via a special purpose acquisition company (SPAC). And it's not hard to see why -- the market not only soured on SPACs, but on unprofitable growth stocks in gene...
23andMe Holding Co. (ME) Q3 2022 Earnings Conference Call Feb 08, 2023, 04:30 PM ET Company Participants Wade Walke - VP, Investor Relations Anne Wojcicki - CEO & Co-Founder Joe Selsavage - Interim CFO & Accounting Officer Kenneth Hillan - Chief Therapeutic...
23andMe ( NASDAQ: ME ) is up 12% in after-hours trading after boosting its 2023 guidance and reporting fiscal 2023 Q3 results that beat on the top and bottom lines. Full year revenue for fiscal 2023 is now projected to be $290M-$300M ($276.54M consensus), with a net loss of $325...
23andMe press release ( NASDAQ: ME ): Q3 GAAP EPS of -$0.20 beats by $0.01 . Revenue of $67M (+17.8% Y/Y) beats by $1.11M . 23andMe is raising its full year guidance following Q3 FY2023 results. Full year revenue for fiscal year 2023, which will end on March 31, 20...
Third quarter revenue grew 18% to $67 million Consumer revenue grew 17% year over year FY2023 financial guidance raised to expected revenue range of $290 to $300 million SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andM...
Toronto, Ontario--(Newsfile Corp. - January 31, 2023) - Moneta Gold Inc. (TSX: ME) (OTCQX: MEAUF) (FSE: MOPA) ("Moneta") is pleased to announce assay results from thirteen (13) resource infill and step-out drill holes on the Windjammer gold deposit at the Tower Gold project (The "Project"), loc...
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
Stocks with share prices under $5 (aka " penny stocks ") are typically too risky to consider. The current economic environment, however, has pushed several intriguing, innovation-oriented companies into penny stock territory. Which beaten-down innovation stocks are worth checking out righ...
Summary NVTA Q4 cash balance remained flat year-over-year at $555M, with 2022 revenue declining by $4M to $122M. Shares appreciated 25% after last week's Q4 purview on optimism over management's ability to trim operating costs, which would provide NVTA with sufficient runway to execute ...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...